FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

C Alm

Research Profile

Chemicals & Drugs

Phenomena

Hydroxylation

Physiology

Geographic Areas

Procedures

Living Beings

Co-author Network

Publications

TOP 3
C Alm; Anne H Berman; Marianne Kristiansson; Tom Palmstierna; Åsa Eriksson; Clara H Gumpert
Treatment patterns among offenders with mental health problems and substance use problems.
C Alm; Anne H Berman; Marianne Kristiansson; Per Lindqvist; Tom Palmstierna; Clara Hellner Gumpert
Gender differences in re-offending among psychiatrically examined Swedish offenders.
Stephen E D Nsimba; Y Aden Abdi; GH Rimoy; Amosy Massele; C Alm; Orjan Ericsson; Lars ´Gustafsson
Comparative in vitro and in vivo study of a sugar-coated chloroquine preparation marketed in Tanzania versus an ordinary brand.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of C Alm (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: C Alm; Anne H Berman; Marianne Kristiansson; Tom Palmstierna; Åsa Eriksson; Clara H Gumpert
Treatment patterns among offenders with mental health problems and substance use problems.
The journal of behavioral health services & research 2011;38(4):497-509.
2010: C Alm; Anne H Berman; Marianne Kristiansson; Per Lindqvist; Tom Palmstierna; Clara Hellner Gumpert
Gender differences in re-offending among psychiatrically examined Swedish offenders.
Criminal behaviour and mental health : CBMH 2010;20(5):323-34.
2001: Stephen E D Nsimba; Y Aden Abdi; GH Rimoy; Amosy Massele; C Alm; Orjan Ericsson; Lars ´Gustafsson
Comparative in vitro and in vivo study of a sugar-coated chloroquine preparation marketed in Tanzania versus an ordinary brand.
Journal of clinical pharmacy and therapeutics 2001;26(1):43-8.
2000: Karin Herrlin; Amosy Massele; GH Rimoy; C Alm; M Rais; Orjan Ericsson; Leif Bertilsson; Lars ´Gustafsson
Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype.
Clinical pharmacology and therapeutics 2000;68(2):189-98.
2000: Juan Antonio Carrillo; Magnus Christensen; Sara Isabel Ramos; C Alm; Marja-Liisa Dahl; Julio Benitez; Leif Bertilsson
Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.
Therapeutic drug monitoring 2000;22(4):409-17.
1999: Agneta Wennerholm; Inger Johansson; Amosy Massele; M Lande; C Alm; Y Aden Abdi; Marja-Liisa Dahl; Magnus Ingelman-Sundberg; Leif Bertilsson; Lars ´Gustafsson
Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype.
Pharmacogenetics 1999;9(6):707-14.
1998: E Arlander; G Ekström; C Alm; Juan Antonio Carrillo; M Bielenstein; Ylva Böttiger; Leif Bertilsson; Lars ´Gustafsson
Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.
Clinical pharmacology and therapeutics 1998;64(5):484-91.
1998: Karin Herrlin; Amosy Massele; Mary Jande; C Alm; Gunnel Tybring; Y A Abdi; Agneta Wennerholm; Inger Johansson; Marja-Liisa Dahl; Leif Bertilsson; Lars ´Gustafsson
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
Clinical pharmacology and therapeutics 1998;64(4):391-401.
1997: B M Emanuelsson; J Persson; C Alm; A Heller; Lars ´Gustafsson
Systemic absorption and block after epidural injection of ropivacaine in healthy volunteers.
Anesthesiology 1997;87(6):1309-17.
1997: B M Emanuelsson; J Persson; S Sandin; C Alm; Lars ´Gustafsson
Intraindividual and interindividual variability in the disposition of the local anesthetic ropivacaine in healthy subjects.
Therapeutic drug monitoring 1997;19(2):126-31.
1996: Ylva Böttiger; P Dostert; M S Benedetti; M Bani; F Fiorentini; M Casati; Italo POggesi; C Alm; G Alvan; Leif Bertilsson
Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.
British journal of clinical pharmacology 1996;42(6):707-11.
1996: Juan Antonio Carrillo; Marja-Liisa Dahl; Jan-Olof Svensson; C Alm; I Rodríguez; Leif Bertilsson
Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.
Clinical pharmacology and therapeutics 1996;60(2):183-90.
1996: Lars Ståhle; C Alm; B Ekquist; B Lundquist; Torbjörn Tomson
Monitoring free extracellular valproic acid by microdialysis in epileptic patients.
Therapeutic drug monitoring 1996;18(1):14-8.
1995: Y A Abdi; G Rimoy; Orjan Ericsson; C Alm; Amosy Massele
Quality of chloroquine preparations marketed in Dar es Salaam, Tanzania.
Lancet 1995;346(8983):1161.
1994: Leif Bertilsson; Juan Antonio Carrillo; Marja-Liisa Dahl; Adrián LLerena; C Alm; U Bondesson; Leif H Lindström; I Rodriguez de la Rubia; S Ramos; Julio Benitez
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
British journal of clinical pharmacology 1994;38(5):471-3.
1994: Marja-Liisa Dahl; Gunnel Tybring; C E Elwin; C Alm; K Andreasson; M Gyllenpalm; Leif Bertilsson
Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism.
Clinical pharmacology and therapeutics 1994;56(2):176-83.
1993: Marja-Liisa Dahl; L Iselius; C Alm; Jan-Olof Svensson; D Lee; Inger Johansson; Magnus Ingelman-Sundberg; Folke Sjöqvist
Polymorphic 2-hydroxylation of desipramine. A population and family study.
European journal of clinical pharmacology 1993;44(5):445-50.
1992: Adrián LLerena; C Alm; Marja-Liisa Dahl; B Ekqvist; Leif Bertilsson
Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.
Therapeutic drug monitoring 1992;14(2):92-7.
1990: M L Dahl-Puustinen; C Alm; Leif Bertilsson; I Christenson; J Ostman; E Thunberg; I Wikström
Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.
British journal of clinical pharmacology 1990;30(3):476-80.
1989: QY Yue; Jan-Olof Svensson; C Alm; Folke Sjöqvist; Juliette Säwe
Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.
British journal of clinical pharmacology 1989;28(6):639-45.
1989: QY Yue; Jan-Olof Svensson; C Alm; Folke Sjöqvist; Juliette Säwe
Interindividual and interethnic differences in the demethylation and glucuronidation of codeine.
British journal of clinical pharmacology 1989;28(6):629-37.
1989: M L Dahl-Puustinen; A Lidén; C Alm; Conny Nordin; Leif Bertilsson
Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings.
Clinical pharmacology and therapeutics 1989;46(1):78-81.
1989: Emilio Sanz; T Villén; C Alm; Leif Bertilsson
S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
Clinical pharmacology and therapeutics 1989;45(5):495-9.